Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
- Determine the impact of each regimen on the disease free and overall survival of
patients with operable breast cancer.
- Determine the ability of docetaxel/capecitabine to downstage primary breast cancer when
administered in the neoadjuvant setting when compared with weekly paclitaxel.
- Determine the ability of each regimen to enhance breast conservation therapy when
administered in the neoadjuvant setting. (See protocol text for additional objectives
and details).